Scipher Medicine, known for its molecular assay supporting rheumatoid arthritis treatment decisions, announced a strategic expansion into data-driven precision medicine and drug discovery across non-oncology diseases. Under new leadership, the company leverages the world’s largest non-oncology clinical transcriptomic dataset, aggregated via numerous partnerships with pharma and informatics firms. This effort aims to close gaps in immunology biomarker discovery and facilitate clinical trial design and real-world evidence generation by combining transcriptomics with advanced health data analytics.